| NCT03338621 |
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients |
https://ClinicalTrials.gov/show/NCT03338621 |
Active, not recruiting |
Global Alliance for TB Drug Development |
2020-04-30 |
| NCT03302949 |
Treating Tuberculosis Wasting With a High-protein Supplement |
https://ClinicalTrials.gov/show/NCT03302949 |
Active, not recruiting |
University of Aarhus |
2020-08-31 |
| NCT03281226 |
RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection |
https://ClinicalTrials.gov/show/NCT03281226 |
Recruiting |
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado |
2019-06-30 |
| NCT03199339 |
A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371 |
https://ClinicalTrials.gov/show/NCT03199339 |
Completed |
Global Alliance for TB Drug Development |
2018-07-08 |
| NCT03199313 |
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid |
https://ClinicalTrials.gov/show/NCT03199313 |
Completed |
Global Alliance for TB Drug Development |
2017-12-16 |
| NCT03174184 |
Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB |
https://ClinicalTrials.gov/show/NCT03174184 |
Recruiting |
Johns Hopkins University |
2021-07-31 |
| NCT03160638 |
Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT03160638 |
Recruiting |
University Medical Center Groningen |
2020-02-01 |
| NCT03086486 |
Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix) |
https://ClinicalTrials.gov/show/NCT03086486 |
Active, not recruiting |
Global Alliance for TB Drug Development |
2020-12-31 |
| NCT02961569 |
Comparison Between Two Strategies for the Diagnosis of TB |
https://ClinicalTrials.gov/show/NCT02961569 |
Completed |
Hopital Lariboisière |
2017-04-30 |
| NCT02912832 |
Prospective Assessment of TBDx Feasibility |
https://ClinicalTrials.gov/show/NCT02912832 |
Completed |
Foundation for Innovative New Diagnostics, Switzerland |
2015-03-31 |
| NCT02836483 |
A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK |
https://ClinicalTrials.gov/show/NCT02836483 |
Completed |
LegoChem Biosciences, Inc |
2019-07-01 |
| NCT02774993 |
Doxycycline in Human Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT02774993 |
Completed |
National University Hospital, Singapore |
2017-06-30 |
| NCT02754765 |
Evaluating Newly Approved Drugs for Multidrug-resistant TB |
https://ClinicalTrials.gov/show/NCT02754765 |
Recruiting |
Médecins Sans Frontières, France |
2020-09-30 |
| NCT02589782 |
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) |
https://ClinicalTrials.gov/show/NCT02589782 |
Recruiting |
Medecins Sans Frontieres, Netherlands |
2020-06-30 |
| NCT02583048 |
Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT02583048 |
Active, not recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) |
2019-01-07 |
| NCT02581527 |
A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT02581527 |
Recruiting |
St George’s, University of London |
2021-01-31 |
| NCT02558842 |
Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight Distance |
https://ClinicalTrials.gov/show/NCT02558842 |
Completed |
Hospital de Clinicas de Porto Alegre |
2015-09-30 |
| NCT02554318 |
Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia |
https://ClinicalTrials.gov/show/NCT02554318 |
Completed |
University of Giessen |
2015-02-28 |
| NCT02481726 |
68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT |
https://ClinicalTrials.gov/show/NCT02481726 |
Completed |
Xijing Hospital |
2014-10-31 |
| NCT02381470 |
Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers |
https://ClinicalTrials.gov/show/NCT02381470 |
Completed |
National University Hospital, Singapore |
2019-09-28 |
| NCT02371681 |
NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis |
https://ClinicalTrials.gov/show/NCT02371681 |
Completed |
National Institutes of Health Clinical Center (CC) |
2017-09-01 |
| NCT02349841 |
Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT02349841 |
Completed |
TASK Applied Science |
2014-12-31 |
| NCT02342886 |
Shortening Treatment by Advancing Novel Drugs |
https://ClinicalTrials.gov/show/NCT02342886 |
Completed |
Global Alliance for TB Drug Development |
2018-01-31 |
| NCT02333799 |
A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT02333799 |
Active, not recruiting |
Global Alliance for TB Drug Development |
2019-01-14 |
| NCT02313610 |
Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT02313610 |
Completed |
Shanghai University of Traditional Chinese Medicine |
2013-03-31 |
| NCT02279875 |
A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001) |
https://ClinicalTrials.gov/show/NCT02279875 |
Completed |
Global Alliance for TB Drug Development |
2016-11-28 |
| NCT02256696 |
Assessing PA-824 for Tuberculosis (the APT Trial) |
https://ClinicalTrials.gov/show/NCT02256696 |
Recruiting |
Johns Hopkins University |
2020-09-30 |
| NCT02219945 |
ENOSE in Pulmonary Tuberculosis in Yogyakarta |
https://ClinicalTrials.gov/show/NCT02219945 |
Completed |
University Medical Center Groningen |
2014-12-31 |
| NCT02193776 |
A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. |
https://ClinicalTrials.gov/show/NCT02193776 |
Completed |
Global Alliance for TB Drug Development |
2016-02-08 |
| NCT02153528 |
Optimization of the TB Treatment Regimen Cascade |
https://ClinicalTrials.gov/show/NCT02153528 |
Completed |
Damien Foundation |
2017-08-01 |
| NCT02106039 |
Pulmonary Tuberculosis Patients With Diabetes Mellitus |
https://ClinicalTrials.gov/show/NCT02106039 |
Completed |
Universitas Padjadjaran |
2017-02-21 |
| NCT02053129 |
Evaluation of PTB Screening in ANC in Lusaka, Zambia |
https://ClinicalTrials.gov/show/NCT02053129 |
Completed |
University of North Carolina, Chapel Hill |
2012-10-31 |
| NCT01927159 |
Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers |
https://ClinicalTrials.gov/show/NCT01927159 |
Completed |
IDRI |
2015-07-31 |
| NCT01785186 |
Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design |
https://ClinicalTrials.gov/show/NCT01785186 |
Completed |
Ludwig-Maximilians - University of Munich |
2014-09-30 |
| NCT01698476 |
Immune Reconstitution in Tuberculosis Disease |
https://ClinicalTrials.gov/show/NCT01698476 |
Completed |
Karolinska Institutet |
2015-08-31 |
| NCT01691534 |
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) |
https://ClinicalTrials.gov/show/NCT01691534 |
Completed |
Global Alliance for TB Drug Development |
2013-04-30 |
| NCT01618422 |
Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in Guangzhou |
https://ClinicalTrials.gov/show/NCT01618422 |
Completed |
Chinese University of Hong Kong |
2013-02-28 |
| NCT01599897 |
Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers |
https://ClinicalTrials.gov/show/NCT01599897 |
Completed |
IDRI |
2014-05-31 |
| NCT01580007 |
Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB) |
https://ClinicalTrials.gov/show/NCT01580007 |
Completed |
International Centre for Diarrhoeal Disease Research, Bangladesh |
2014-12-31 |
| NCT01517022 |
Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT01517022 |
Completed |
All India Institute of Medical Sciences, New Delhi |
2016-09-30 |
| NCT01498419 |
Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002) |
https://ClinicalTrials.gov/show/NCT01498419 |
Completed |
Global Alliance for TB Drug Development |
2013-04-30 |
| NCT01392911 |
Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB |
https://ClinicalTrials.gov/show/NCT01392911 |
Completed |
Radboud University |
2018-07-31 |
| NCT01363765 |
Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil |
https://ClinicalTrials.gov/show/NCT01363765 |
Completed |
Ataulpho de Paiva Foundation |
2012-10-31 |
| NCT04433195 |
Xpert MTB/RIF Test in the Diagnosis of Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT04433195 |
Recruiting |
Taipei Medical University WanFang Hospital |
2021-04-30 |
| NCT04122404 |
POC Strategies to Improve TB Care in Advanced HIV Disease |
https://ClinicalTrials.gov/show/NCT04122404 |
Recruiting |
University of Southern Denmark |
2021-08-15 |
| NCT04044001 |
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA) |
https://ClinicalTrials.gov/show/NCT04044001 |
Recruiting |
Ludwig-Maximilians - University of Munich |
2020-10-31 |
| NCT03967353 |
Study on the Management Model of “Home Treatment” for Tuberculosis Patients |
https://ClinicalTrials.gov/show/NCT03967353 |
Recruiting |
Beijing Chest Hospital |
2022-03-31 |
| NCT03882177 |
StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis |
https://ClinicalTrials.gov/show/NCT03882177 |
Active, not recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) |
2020-12-31 |
| NCT03851159 |
Nyaditum Resae® as a Co-adjuvant During Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota |
https://ClinicalTrials.gov/show/NCT03851159 |
Recruiting |
University of Stellenbosch |
2021-12-31 |
| NCT03776500 |
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing |
https://ClinicalTrials.gov/show/NCT03776500 |
Recruiting |
Innovative Medicines for Tuberculosis |
2019-09-30 |
| NCT03758612 |
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults |
https://ClinicalTrials.gov/show/NCT03758612 |
Completed |
Global Alliance for TB Drug Development |
2020-03-14 |
| NCT03702738 |
Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT03702738 |
Recruiting |
The Aurum Institute NPC |
2020-10-30 |
| NCT03678688 |
A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT03678688 |
Recruiting |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2021-06-30 |
| NCT03590600 |
A Single Ascending Dose Study of BTZ043 |
https://ClinicalTrials.gov/show/NCT03590600 |
Completed |
Ludwig-Maximilians - University of Munich |
2018-08-14 |
| NCT03561753 |
Pilot Clinical Trial of PRS TB Regimen I - Phase II |
https://ClinicalTrials.gov/show/NCT03561753 |
Enrolling by invitation |
Shanghai Pulmonary Hospital, Shanghai, China |
2019-12-31 |
| NCT03557281 |
An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT03557281 |
Recruiting |
GlaxoSmithKline |
2022-04-29 |
| NCT03519425 |
A Pragmatic Randomised Study to Optimise Screening, Prevention and Care for Tuberculosis in Malawi |
https://ClinicalTrials.gov/show/NCT03519425 |
Active, not recruiting |
Liverpool School of Tropical Medicine |
2019-12-31 |
| NCT03512249 |
Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence |
https://ClinicalTrials.gov/show/NCT03512249 |
Recruiting |
Aeras |
2022-04-06 |
| NCT03478033 |
Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis |
https://ClinicalTrials.gov/show/NCT03478033 |
Recruiting |
Shanghai Public Health Clinical Center |
2020-06-01 |
| NCT03474198 |
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis |
https://ClinicalTrials.gov/show/NCT03474198 |
Recruiting |
University College, London |
2022-03-12 |
| NCT03423030 |
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation |
https://ClinicalTrials.gov/show/NCT03423030 |
Completed |
Innovative Medicines for Tuberculosis |
2018-03-28 |
| NCT01242592 |
Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT01242592 |
Completed |
NMP Medical Research Institute |
NA |
| NCT01218217 |
Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB |
https://ClinicalTrials.gov/show/NCT01218217 |
Completed |
Ludwig-Maximilians - University of Munich |
2011-09-30 |
| NCT01215851 |
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) |
https://ClinicalTrials.gov/show/NCT01215851 |
Completed |
Global Alliance for TB Drug Development |
2011-05-31 |
| NCT01215110 |
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001) |
https://ClinicalTrials.gov/show/NCT01215110 |
Completed |
Global Alliance for TB Drug Development |
2010-08-31 |
| NCT01162486 |
Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT01162486 |
Completed |
Johns Hopkins University |
2011-02-28 |
| NCT01130311 |
Replacement of Vitamin D in Patients With Active Tuberculosis |
https://ClinicalTrials.gov/show/NCT01130311 |
Completed |
Aga Khan University |
2010-04-30 |
| NCT01043575 |
High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis |
https://ClinicalTrials.gov/show/NCT01043575 |
Completed |
Centers for Disease Control and Prevention |
2010-05-31 |
| NCT01011543 |
Induced Sputum Versus Bronchoscopy in Smear Negative Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT01011543 |
Completed |
Centre Hospitalier Universitaire Saint Pierre |
2015-12-31 |
| NCT00944021 |
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010) |
https://ClinicalTrials.gov/show/NCT00944021 |
Completed |
Global Alliance for TB Drug Development |
2010-01-31 |
| NCT00939419 |
The Effectiveness of Health Facility-based and Community-based Care for Tuberculosis |
https://ClinicalTrials.gov/show/NCT00939419 |
Completed |
University of Leeds |
2006-12-31 |
| NCT00933790 |
Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT00933790 |
Completed |
Tuberculosis Research Centre, India |
2016-12-31 |
| NCT00864383 |
Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT00864383 |
Completed |
Global Alliance for TB Drug Development |
2013-10-31 |
| NCT02465216 |
Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion |
https://ClinicalTrials.gov/show/NCT02465216 |
Completed |
IDRI |
2017-01-31 |
| NCT00814671 |
Study of Daily Rifapentine for Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT00814671 |
Completed |
Johns Hopkins University |
2013-06-30 |
| NCT01945905 |
Cost-effectiveness of Two Forms of DOTS in a Demonstration Area of the DOTS Strategy in Colombia |
https://ClinicalTrials.gov/show/NCT01945905 |
Completed |
Fundación FES |
2014-08-31 |
| NCT00801606 |
Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT00801606 |
Completed |
All India Institute of Medical Sciences, New Delhi |
2012-06-30 |
| NCT03722472 |
Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults |
https://ClinicalTrials.gov/show/NCT03722472 |
Active, not recruiting |
IDRI |
2020-03-31 |
| NCT03044158 |
GeneXpert Performance Evaluation for Linkage to Tuberculosis Care |
https://ClinicalTrials.gov/show/NCT03044158 |
Active, not recruiting |
University of California, San Francisco |
2020-03-01 |
| NCT02821832 |
Using Biomarkers to Predict TB Treatment Duration |
https://ClinicalTrials.gov/show/NCT02821832 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-12-31 |
| NCT00760149 |
Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT00760149 |
Completed |
Radboud University |
2013-09-30 |
| NCT00727844 |
Linezolid to Treat Extensively-Drug Resistant Tuberculosis |
https://ClinicalTrials.gov/show/NCT00727844 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2012-10-31 |
| NCT00694629 |
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment |
https://ClinicalTrials.gov/show/NCT00694629 |
Completed |
Centers for Disease Control and Prevention |
2013-06-30 |
| NCT00685360 |
A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) |
https://ClinicalTrials.gov/show/NCT00685360 |
Completed |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2010-06-30 |
| NCT00677339 |
L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB) |
https://ClinicalTrials.gov/show/NCT00677339 |
Completed |
Menzies School of Health Research |
2010-02-28 |
| NCT00567840 |
PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT00567840 |
Completed |
Global Alliance for TB Drug Development |
2007-12-31 |
| NCT00495339 |
MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT00495339 |
Completed |
Sanofi |
2008-04-30 |
| NCT00425113 |
Metronidazole for Pulmonary Tuberculosis (South Korea) |
https://ClinicalTrials.gov/show/NCT00425113 |
Completed |
National Institutes of Health Clinical Center (CC) |
2012-10-31 |
| NCT00419068 |
Trial of Adjunctive Vitamin D in Tuberculosis Treatment |
https://ClinicalTrials.gov/show/NCT00419068 |
Completed |
Barts & The London NHS Trust |
2009-09-30 |
| NCT00401271 |
Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT00401271 |
Completed |
Otsuka Frankfurt Research Institute GmbH |
NA |
| NCT00396084 |
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT00396084 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2007-11-23 |
| NCT00366470 |
A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients |
https://ClinicalTrials.gov/show/NCT00366470 |
Completed |
Christian Medical College, Vellore, India |
2012-05-31 |
| NCT00341328 |
Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients. |
https://ClinicalTrials.gov/show/NCT00341328 |
Completed |
Ministry of Science and Technology, India |
2011-10-31 |
| NCT00311298 |
Nutrition, Diabetes and Pulmonary TB/HIV |
https://ClinicalTrials.gov/show/NCT00311298 |
Completed |
University of Copenhagen |
2009-03-31 |
| NCT00298870 |
Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) |
https://ClinicalTrials.gov/show/NCT00298870 |
Completed |
Osaka University |
NA |
| NCT00265226 |
Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients |
https://ClinicalTrials.gov/show/NCT00265226 |
Completed |
Ministry of Science and Technology, India |
2010-12-31 |
| NCT00140309 |
TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment |
https://ClinicalTrials.gov/show/NCT00140309 |
Completed |
Centers for Disease Control and Prevention |
NA |
| NCT00057434 |
Vitamin A Therapy for Tuberculosis |
https://ClinicalTrials.gov/show/NCT00057434 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00023335 |
TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis |
https://ClinicalTrials.gov/show/NCT00023335 |
Completed |
Centers for Disease Control and Prevention |
NA |
| NCT00000796 |
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients. |
https://ClinicalTrials.gov/show/NCT00000796 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00000778 |
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin |
https://ClinicalTrials.gov/show/NCT00000778 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00001407 |
Interferon Gamma for Drug Resistant Tuberculosis |
https://ClinicalTrials.gov/show/NCT00001407 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00004444 |
Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis |
https://ClinicalTrials.gov/show/NCT00004444 |
Completed |
FDA Office of Orphan Products Development |
NA |